4Fr系统经皮动静脉瘘建立:EASE研究临床经验
本研究为单中心单臂前瞻性研究,评估4Fr经皮动静脉瘘(endoAVF)系统在32例血液透析患者中的安全性和有效性。技术成功率100%,6个月一期和累积通畅率分别为83%和87%,90天生理适用性达91%,功能穿刺率74%,装置或操作相关严重不良事件率3%。
要点
- 4Fr endoAVF系统技术成功率100%,严重不良事件率3%。
- 6个月一期和累积通畅率分别为83%和87%。
- 90天生理适用性91%,功能穿刺率74%,平均穿刺时间43±14天。
核心结论
- 4Fr endoAVF系统允许多种入路和瘘管创建部位选择,以适应个体解剖。
- 结局与先前代endoAVF技术相当,且因使用腕部动脉入路可能具有更好的安全性。
研究设计与样本
- 多操作者、单中心、单臂、前瞻性研究,评估4Fr endoAVF系统在血液透析患者中的安全性和有效性。
主要发现
- 所有32例患者成功创建endoAVF(20例桡动脉-桡静脉,12例尺动脉-尺静脉),技术成功率100%。
- 装置或操作相关严重不良事件率3%(1/32),1例静脉导丝穿孔经覆膜支架成功处理。
- 6个月一期通畅率83%,累积通畅率87%,干预率0.21/患者年。
- 90天生理适用性(目标流量≥500 ml/min且穿刺血管直径≥4 mm)达91%(29/32)。
- 90天成功双针穿刺率78%(21/27),平均穿刺时间43±14天;功能穿刺率74%(20/27),所有功能穿刺患者均在90天随访前拔除中心静脉导管。
关键数值与推荐
- 生理适用性定义为目标流量≥500 ml/min且穿刺血管直径≥4 mm,90天时91%(29/32)达到。
- 功能穿刺定义为1个月内三分之二透析 sessions 成功双针穿刺,95%(20/21)成功穿刺患者达到,总体率74%(20/27)。
临床怎么用
- 4Fr endoAVF系统可提供多种入路和瘘管创建部位选择,适应个体解剖。
- 术后90天生理适用性和功能穿刺率较高,多数患者可拔除中心静脉导管。
局限性
- 单中心、单臂、小样本(32例)研究,随访仅6个月。
- 缺乏对照组,结果需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The use of arteriovenous fistula (AVF) is hampered by long surgical wait times, slow maturation, and upwards of 60% that do not mature. We describe our clinical experience in using a system with a 4F catheter profile for endovascular AVF creation in patients on hemodialysis. METHODS: This was a multioperator, single-center, single-arm, prospective study intended to evaluate safety and efficacy of a 4 Fr endovascular AVF (endoAVF) system for the creation of vascular access in hemodialysis patients. The study was performed after institutional review board approval at Italian Hospital (Asuncion, Paraguay). Patients were followed up at regular intervals through 6 months to determine procedural, maturation, and cannulation success as well as intervention rate and patency. RESULTS: From May to November 2016, 32 patients underwent the endoAVF procedure with no device-related adverse events. An endoAVF was successfully created in the proximal forearm for all 32 patients (20 between the radial artery and radial vein; 12 between the ulnar artery and ulnar vein). Wrist access was used for 72% (23/32) of the procedures for the arterial catheter and 59% (19/32) of the procedures for the venous catheter. The device successfully created an endoAVF in every patient for a technical success rate of 100% (32/32). The device- or procedure-related serious adverse event rate was 3% (1/32); one patient experienced a venous guidewire perforation successfully managed with a stent graft. Primary and cumulative patency rates through 6 months were 83% and 87%, respectively, with an intervention rate of 0.21 per patient-year. Physiological suitability, as defined by target flow rates ≥500 ml/min and cannulation vessel diameters ≥4 mm, was achieved in 91% (29/32) of patients by 90 days. Successful 2-needle cannulation was achieved in 78% (21/27) by 90 days, with mean time to cannulation of 43 ± 14 days. Functional cannulation, as defined by successful 2-needle cannulation for two-thirds of the dialysis sessions within 1 month, was achieved in 95% (20/21) of the patients who were successfully cannulated for an overall rate of 74% (20/27). All patients who achieved functional cannulation had their central venous catheters (CVCs) removed before the 90-day follow-up for a CVC removal rate of 74% (20/27). CONCLUSIONS: The 4 Fr endoAVF system allowed for multiple access and fistula creation site options to tailor the procedure to individual patient anatomy. Furthermore, the outcomes are comparable to previous generation endoAVF technology, with a potentially improved safety profile because of the use of arteries at the wrist for access.
引用
- Berland TL, Clement J, Griffin J, et al. Endovascular Creation of Arteriovenous Fistulae for Hemodialysis Access with a 4 Fr Device: Clinical Experience from the EASE Study. Ann Vasc Surg. 2019. PMID: 31075457. doi:10.1016/j.avsg.2019.02.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。